Biomarkers predicting clinical benefit

Fact or fiction?

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Preoperative therapy is increasingly used in operable disease to improve the chance for breast-conservative surgery. Moreover, this strategy allows for a better definition of patient prognosis. Independently from stage at diagnosis and breast cancer subtype, the achievement of a pathological complete response (pCR) is a surrogate marker for long-term outcome. The likelihood of pCR depends on tumor biology, being poorly differentiated tumors with ductal histology, absence of hormone receptors, and high proliferation rate those with a higher chance of achieving a CR. However, pCR is a late efficacy parameter that can be evaluated at the end of the preoperative treatment; moreover, a pCR is achieved in a minority of patients and is not an appropriate efficacy measure for neoadjuvant endocrine therapy. The predictive role of tumor biomarkers such as p53, microtubule-associated tau protein, and poly (ADP-ribose) polymerase will be reviewed along with potential markers of early treatment effect.

Original languageEnglish
Pages (from-to)63-66
Number of pages4
JournalJournal of the National Cancer Institute - Monographs
Issue number43
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Biomarkers
tau Proteins
Neoadjuvant Therapy
Microtubule-Associated Proteins
Poly(ADP-ribose) Polymerases
Tumor Biomarkers
Neoplasms
Histology
Breast
Therapeutics
Hormones
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biomarkers predicting clinical benefit : Fact or fiction? / Guarneri, Valentina; Barbieri, Elena; Conte, PierFranco.

In: Journal of the National Cancer Institute - Monographs, No. 43, 10.2011, p. 63-66.

Research output: Contribution to journalArticle

@article{4e4604a035ee4df28d2f054cc87118e3,
title = "Biomarkers predicting clinical benefit: Fact or fiction?",
abstract = "Preoperative therapy is increasingly used in operable disease to improve the chance for breast-conservative surgery. Moreover, this strategy allows for a better definition of patient prognosis. Independently from stage at diagnosis and breast cancer subtype, the achievement of a pathological complete response (pCR) is a surrogate marker for long-term outcome. The likelihood of pCR depends on tumor biology, being poorly differentiated tumors with ductal histology, absence of hormone receptors, and high proliferation rate those with a higher chance of achieving a CR. However, pCR is a late efficacy parameter that can be evaluated at the end of the preoperative treatment; moreover, a pCR is achieved in a minority of patients and is not an appropriate efficacy measure for neoadjuvant endocrine therapy. The predictive role of tumor biomarkers such as p53, microtubule-associated tau protein, and poly (ADP-ribose) polymerase will be reviewed along with potential markers of early treatment effect.",
author = "Valentina Guarneri and Elena Barbieri and PierFranco Conte",
year = "2011",
month = "10",
doi = "10.1093/jncimonographs/lgr021",
language = "English",
pages = "63--66",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "43",

}

TY - JOUR

T1 - Biomarkers predicting clinical benefit

T2 - Fact or fiction?

AU - Guarneri, Valentina

AU - Barbieri, Elena

AU - Conte, PierFranco

PY - 2011/10

Y1 - 2011/10

N2 - Preoperative therapy is increasingly used in operable disease to improve the chance for breast-conservative surgery. Moreover, this strategy allows for a better definition of patient prognosis. Independently from stage at diagnosis and breast cancer subtype, the achievement of a pathological complete response (pCR) is a surrogate marker for long-term outcome. The likelihood of pCR depends on tumor biology, being poorly differentiated tumors with ductal histology, absence of hormone receptors, and high proliferation rate those with a higher chance of achieving a CR. However, pCR is a late efficacy parameter that can be evaluated at the end of the preoperative treatment; moreover, a pCR is achieved in a minority of patients and is not an appropriate efficacy measure for neoadjuvant endocrine therapy. The predictive role of tumor biomarkers such as p53, microtubule-associated tau protein, and poly (ADP-ribose) polymerase will be reviewed along with potential markers of early treatment effect.

AB - Preoperative therapy is increasingly used in operable disease to improve the chance for breast-conservative surgery. Moreover, this strategy allows for a better definition of patient prognosis. Independently from stage at diagnosis and breast cancer subtype, the achievement of a pathological complete response (pCR) is a surrogate marker for long-term outcome. The likelihood of pCR depends on tumor biology, being poorly differentiated tumors with ductal histology, absence of hormone receptors, and high proliferation rate those with a higher chance of achieving a CR. However, pCR is a late efficacy parameter that can be evaluated at the end of the preoperative treatment; moreover, a pCR is achieved in a minority of patients and is not an appropriate efficacy measure for neoadjuvant endocrine therapy. The predictive role of tumor biomarkers such as p53, microtubule-associated tau protein, and poly (ADP-ribose) polymerase will be reviewed along with potential markers of early treatment effect.

UR - http://www.scopus.com/inward/record.url?scp=84855179710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855179710&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgr021

DO - 10.1093/jncimonographs/lgr021

M3 - Article

SP - 63

EP - 66

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 43

ER -